**PRODUCT INFORMATION**

**Nevirapine**  
*Item No. 15117*

**CAS Registry No.:** 129618-40-2  
**Formal Name:** 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one  
**Synonyms:** BI-RG 587, NSC 641530, NVP  
**MF:** C_{15}H_{14}N_{4}O  
**FW:** 266.3  
**Purity:** ≥98%  
**UV/Vis.:** $\lambda_{\text{max}}$: 213, 284 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥2 years

*Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.*

**Laboratory Procedures**

Nevirapine is supplied as a crystalline solid. A stock solution may be made by dissolving the nevirapine in the solvent of choice. Nevirapine is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of nevirapine in these solvents is approximately 2.5 and 5 mg/ml, respectively.

Nevirapine is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, nevirapine should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Nevirapine has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

**Description**

Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It binds to HIV-1 reverse transcriptase and inhibits RNA plus-strand initiation (IC$_{50}$ = 0.45 μM). Nevirapine prevents seroconversion and viremia in a chimpanzee model of HIV-1 infection.

**Formulations**

Formulations containing nevirapine have been used in combination therapy for the treatment of HIV-1 infection.

**References**